Search Results - Changchun Deng
- Showing 1 - 5 results of 5
-
1
Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79 by Andrew L. Deng, Yu Ri Kim, Emily A. Lichtenstein, Owen A. O’Connor, Changchun Deng
Published in Haematologica (2017-07-01)Get full text
Article -
2
Plasmablastic lymphoma in an HIV patient with cutaneous presentation: A case of remarkable remission in a typically refractory disease by Ijeuru Chikeka, MD, Marc Grossman, MD, FACP, Changchun Deng, MD, PhD, Alice T. Jacob, RN, Sameera Husain, MD
Published in JAAD Case Reports (2020-03-01)Get full text
Article -
3
Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors by Dandan Yuan, Yali Gao, Lin Xia, Han Liu, Xingye Wu, Xueyan Ding, Yudan Huang, Changchun Deng, Jin Li, Wenqi Dai, Jieqing Liu, Junjie Ma
Published in Journal of Enzyme Inhibition and Medicinal Chemistry (2025-12-01)Get full text
Article -
4
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy by Lorenzo Falchi, Ahmed Sawas, Changchun Deng, Jennifer E. Amengual, Donald S. Colbourn, Emily A. Lichtenstein, Karen A. Khan, Lawrence H. Schwartz, Owen A. O’Connor
Published in Journal of Hematology & Oncology (2016-11-01)Get full text
Article -
5
P624: PHASE 1 STUDY OF JNJ-67856633, A FIRST-IN-HUMAN HIGHLY SELECTIVE MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEU... by Matko Kalac, Mark Hertzberg, Chan Cheah, Vincent Ribrag, Pablo Abrisquet Acosta, Stephen Opat, Emmanuel Bachy, Loïc Ysebaert, Lihua Qiu, Shuhua Yi, Noriko Nishimura, Charlotte Lemech, Jacqueline Bussolari, Changchun Deng, Tianbao Lu, Liang Xiu, Sandy Van Hemelryck, Ulrike Philippar, Yue Guo, Virginie Soete, Isabel Soriano, Nele Fourneau, John Gerecitano, Franck Morschhauser
Published in HemaSphere (2023-08-01)Get full text
Article
